Pharmacy Benefits Will Change: January 1, 2021

Date: October 15, 2020 To: Health Plan of San Joaquin (HPSJ) Provider Network From: Health Plan of San Joaquin Subject: Pharmacy Benefits Will Change: January 1, 2021 Business: Medi-Cal Effective January 1, 2021 – Health Plan of San Joaquin pharmacy benefits will be transitioned to and administered by the new agency, Medi-Cal Rx. ALL outpatient [...]

Read more

2020 Immunization Updates: Vaccination during COVID-19, Flu, HepA, and Tdap

Each year, the California Medi-Cal Drug Use Review (DUR) program issues an annual summary of updates on immunization guidelines, products, and/or research in collaboration with the California Department of Public Health (CDPH) Immunization Branch. For reference, the recommended immunization schedules for 2020 in the United States can be accessed on the Centers for Disease Control […]

Read more

Formulary Update – Effective December 16, 2020

Date: October 8, 2020 To: Health Plan of San Joaquin (HPSJ) Physicians, Providers, and Pharmacies From: Health Plan of San Joaquin Pharmacy and Therapeutics Committee Subject: Formulary Update - Effective December 16, 2020 Business: Medi-Cal Effective December 16, 2020, the Pharmacy and Therapeutics Committee has approved the following changes. Additions to the Formulary: Upadacitinib (Rinvoq) [...]

Read more

Clinical Review: 2020 Standards of Care for Treatment of Type 2 Diabetes

Learning Objectives: Review recommendations provided in the American Diabetes Association (ADA) Standards of Medical Care – 2020 addressing the pharmacologic approach to glycemic control for patients with type 2 diabetes Describe patient factors to consider when prescribing antihyperglycemic agents Understand the boxed warnings for antihyperglycemic agents Download the full documente here: Key Points: Diabetes is […]

Read more

Pharmacy Update: Oncology Medicine

Date: August 31, 2020 To: Health Plan of San Joaquin (HPSJ) Physicians, Providers, and Pharmacies From: Health Plan of San Joaquin Subject: Pharmacy Update: Oncology Medicine Business: Medi-Cal Effective 11/2/2020, all oncology medications will require prior authorizations. Please note that the following list of the medications is not all inclusive. Download the Oncology Medicine PDF [...]

Read more

Immediate Action Required – Epinephrine Auto Injector Devices

Date: June 17, 2020 To: Health Plan of San Joaquin (HPSJ) Pharmacies and Providers & Practices From: HPSJ Pharmacy Department Subject: Immediate Action Required – Epinephrine Auto Injector Devices Business: Medi-Cal We are sending this alert because your patient(s) may have filled a prescription for Epinephrine Auto-Injector Device since December 20, 2018. FDA is alerting […]

Read more

Clinical Guideline: Reproductive Health in Rheumatic and Musculoskeletal Diseases

The American College of Rheumatology recently published the organization’s first guideline on how to manage reproductive health issues in patients with rheumatic and musculoskeletal diseases (RMDs). Patients with RMDs face unique challenges as pregnancy may be associated with serious maternal or adverse fetal outcomes; furthermore, it is difficult to avoid use of medications in patients […]

Read more

NP Thyroid recall provider alert

Date: May 28, 2020 To: Health Plan of San Joaquin (HPSJ) Pharmacies and Providers From: HPSJ Pharmacy Department Subject: NP Thyroid Recall Business: Medi-Cal We are sending this alert because your patients may have filled a prescription for NP Thyroid 30mg, 60mg or 90mg within the last six months (180 days). With FDA knowledge, Acella […]

Read more

Formulary Update Effective 8/3/2020

Date: May 22, 2020 To: Health Plan of San Joaquin (HPSJ) Physicians, Providers, and Pharmacies From: HPSJ Pharmacy and Therapeutics Committee Subject: Formulary Update Business: Medi-Cal Effective August 3, 2020, the Pharmacy and Therapeutics Committee has approved the following changes. Additions to the Formulary: 1. Dulaglutide (Trulicity) 0.75 mg/0.5 mL, 1.5mg/0.5ml pen: PA required. Reserved [...]

Read more

Drug Safety Communication: Withdrawal of All Ranitidine Products

Drug Safety Communication: Withdrawal of All Ranitidine Products Ranitidine is a histamine-2 blocker commonly used as an over-the-counter (OTC) medication to relieve and prevent heartburn. Prescription-strength ranitidine is also used to treat and prevent more serious ulcers in the stomach and intestines. On April 1, 2020, the U.S. Food and Drug Administration (FDA) requested a […]

Read more

1 2 3 5
top
X